182 related articles for article (PubMed ID: 21321479)
1. Structure-based development of specific inhibitors for individual cathepsins and their medical applications.
Katunuma N
Proc Jpn Acad Ser B Phys Biol Sci; 2011; 87(2):29-39. PubMed ID: 21321479
[TBL] [Abstract][Full Text] [Related]
2. Study of the functional share of lysosomal cathepsins by the development of specific inhibitors.
Katunuma N; Matsui A; Kakegawa T; Murata E; Asao T; Ohba Y
Adv Enzyme Regul; 1999; 39():247-60. PubMed ID: 10470376
[TBL] [Abstract][Full Text] [Related]
3. Structure-based development of pyridoxal propionate derivatives as specific inhibitors of cathepsin K in vitro and in vivo.
Katunuma N; Matsui A; Inubushi T; Murata E; Kakegawa H; Ohba Y; Turk D; Turk V; Tada Y; Asao T
Biochem Biophys Res Commun; 2000 Jan; 267(3):850-4. PubMed ID: 10673380
[TBL] [Abstract][Full Text] [Related]
4. Insights into the roles of cathepsins in antigen processing and presentation revealed by specific inhibitors.
Katunuma N; Matsunaga Y; Himeno K; Hayashi Y
Biol Chem; 2003 Jun; 384(6):883-90. PubMed ID: 12887055
[TBL] [Abstract][Full Text] [Related]
5. Chalcones, semicarbazones and pyrazolines as inhibitors of cathepsins B, H and L.
Raghav N; Kaur R
Int J Biol Macromol; 2015 Sep; 80():710-24. PubMed ID: 26193682
[TBL] [Abstract][Full Text] [Related]
6. Identification of selective, nonpeptidic nitrile inhibitors of cathepsin s using the substrate activity screening method.
Patterson AW; Wood WJ; Hornsby M; Lesley S; Spraggon G; Ellman JA
J Med Chem; 2006 Oct; 49(21):6298-307. PubMed ID: 17034136
[TBL] [Abstract][Full Text] [Related]
7. Structure-based design of specific cathepsin inhibitors and their application to protection of bone metastases of cancer cells.
Katunuma N; Tsuge H; Nukatsuka M; Asao T; Fukushima M
Arch Biochem Biophys; 2002 Jan; 397(2):305-11. PubMed ID: 11795887
[TBL] [Abstract][Full Text] [Related]
8. A novel class of nonpeptidic biaryl inhibitors of human cathepsin K.
Robichaud J; Oballa R; Prasit P; Falgueyret JP; Percival MD; Wesolowski G; Rodan SB; Kimmel D; Johnson C; Bryant C; Venkatraman S; Setti E; Mendonca R; Palmer JT
J Med Chem; 2003 Aug; 46(17):3709-27. PubMed ID: 12904076
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 1.
Liu H; Tully DC; Epple R; Bursulaya B; Li J; Harris JL; Williams JA; Russo R; Tumanut C; Roberts MJ; Alper PB; He Y; Karanewsky DS
Bioorg Med Chem Lett; 2005 Nov; 15(22):4979-84. PubMed ID: 16183279
[TBL] [Abstract][Full Text] [Related]
10. 2-Cyano-pyrimidines: a new chemotype for inhibitors of the cysteine protease cathepsin K.
Altmann E; Aichholz R; Betschart C; Buhl T; Green J; Irie O; Teno N; Lattmann R; Tintelnot-Blomley M; Missbach M
J Med Chem; 2007 Feb; 50(4):591-4. PubMed ID: 17256925
[TBL] [Abstract][Full Text] [Related]
11. Keto-1,3,4-oxadiazoles as cathepsin K inhibitors.
Palmer JT; Hirschbein BL; Cheung H; McCarter J; Janc JW; Yu ZW; Wesolowski G
Bioorg Med Chem Lett; 2006 Jun; 16(11):2909-14. PubMed ID: 16546382
[TBL] [Abstract][Full Text] [Related]
12. Structure based development of novel specific inhibitors for cathepsin L and cathepsin S in vitro and in vivo.
Katunuma N; Murata E; Kakegawa H; Matsui A; Tsuzuki H; Tsuge H; Turk D; Turk V; Fukushima M; Tada Y; Asao T
FEBS Lett; 1999 Sep; 458(1):6-10. PubMed ID: 10518923
[TBL] [Abstract][Full Text] [Related]
13. 3-hydroxy-3-methylglutaryl coenzyme A reductase is sterol-dependently cleaved by cathepsin L-type cysteine protease in the isolated endoplasmic reticulum.
Moriyama T; Wada M; Urade R; Kito M; Katunuma N; Ogawa T; Simoni RD
Arch Biochem Biophys; 2001 Feb; 386(2):205-12. PubMed ID: 11368343
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of cathepsin K reduces bone erosion, cartilage degradation and inflammation evoked by collagen-induced arthritis in mice.
Svelander L; Erlandsson-Harris H; Astner L; Grabowska U; Klareskog L; Lindstrom E; Hewitt E
Eur J Pharmacol; 2009 Jun; 613(1-3):155-62. PubMed ID: 19358841
[TBL] [Abstract][Full Text] [Related]
15. Discovery and SAR of novel pyrazole-based thioethers as cathepsin S inhibitors: part 1.
Lee-Dutra A; Wiener DK; Arienti KL; Liu J; Mani N; Ameriks MK; Axe FU; Gebauer D; Desai PJ; Nguyen S; Randal M; Thurmond RL; Sun S; Karlsson L; Edwards JP; Jones TK; Grice CA
Bioorg Med Chem Lett; 2010 Apr; 20(7):2370-4. PubMed ID: 20153648
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and investigation of dihydroxychalcones as calpain and cathepsin inhibitors.
Baek KH; Karki R; Lee ES; Na Y; Kwon Y
Bioorg Chem; 2013 Dec; 51():24-30. PubMed ID: 24095934
[TBL] [Abstract][Full Text] [Related]
17. Differential cathepsin responses to inhibitor-induced feedback: E-64 and cystatin C elevate active cathepsin S and suppress active cathepsin L in breast cancer cells.
Wilder CL; Walton C; Watson V; Stewart FAA; Johnson J; Peyton SR; Payne CK; Odero-Marah V; Platt MO
Int J Biochem Cell Biol; 2016 Oct; 79():199-208. PubMed ID: 27592448
[TBL] [Abstract][Full Text] [Related]
18. SAR studies of some acetophenone phenylhydrazone based pyrazole derivatives as anticathepsin agents.
Raghav N; Singh M
Bioorg Chem; 2017 Dec; 75():38-49. PubMed ID: 28915464
[TBL] [Abstract][Full Text] [Related]
19. Participation of a cathepsin L-type protease in the activation of caspase-3.
Ishisaka R; Utsumi T; Kanno T; Arita K; Katunuma N; Akiyama J; Utsumi K
Cell Struct Funct; 1999 Dec; 24(6):465-70. PubMed ID: 10698261
[TBL] [Abstract][Full Text] [Related]
20. Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.
Tavares FX; Boncek V; Deaton DN; Hassell AM; Long ST; Miller AB; Payne AA; Miller LR; Shewchuk LM; Wells-Knecht K; Willard DH; Wright LL; Zhou HQ
J Med Chem; 2004 Jan; 47(3):588-99. PubMed ID: 14736240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
